Logotype for MindWalk Holdings Corp

MindWalk (HYFT) Q4 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for MindWalk Holdings Corp

Q4 2024 earnings summary

2 Feb, 2026

Executive summary

  • Achieved fifth consecutive quarter of record revenue and record fiscal year revenues, reaching $24.5 million in FY 2024, a 19% year-over-year increase, driven by end-to-end services, AI-driven innovations, and demand for antibody discovery.

  • Successfully launched LENSai API and Vector Search software, accelerating SaaS commercialization, attracting early access partners, and generating commercial traction and industry recognition.

  • Expanded European lab facilities and capabilities, fueling growth in antibody discovery, protein production, and fee-for-service work.

  • Appointed Kristin Taylor as permanent CFO, bringing experience in early-stage and growth companies.

  • Strategic investments in AI, notably BioStrand's LENSai platform, have begun generating commercial traction and industry recognition.

Financial highlights

  • Fiscal 2024 revenue reached $24.5 million, up from $20.7 million in FY 2023, outpacing industry averages.

  • Gross profit margin was 49%, down from 56% last year due to expansion costs and inflation lag; gross profit was $12.1 million, up from $11.6 million.

  • Operating expenses (excluding impairment) decreased 30% to CAD 26 million, mainly from reduced R&D spend; R&D expenses for FY 2024 were $4.0 million, down from $14.1 million.

  • Net loss was $27.2 million, including $15 million in non-cash impairments; adjusted net loss (excluding impairments) was $12.1 million, improved from $24.1 million last year.

  • Cash burn reduced significantly to $4.2 million from $19.8 million in FY 2023; ended year with $3.5 million in unrestricted cash.

Outlook and guidance

  • Expects continued revenue growth in fiscal 2025, driven by B Cell Select platform, expanded manufacturing, and LENSai software.

  • Ongoing expansion of laboratory facilities and service offerings, including new equipment and enhanced antibody discovery technologies, is expected to drive growth.

  • Strategic collaborations and commercialization of LENSai API, including AWS Marketplace rollout, are anticipated to support recurring revenue streams.

  • Anticipates further revenue from partnerships and fee-for-service projects powered by LENSai.

  • Focus remains on operational efficiency, financial prudence, and sustained profitability improvements.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more